📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell Carcinoma (2022)

First Author: Voss M

Attributed to: Development of a 'humanised' model for renal cancer funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1158/1078-0432.ccr-21-4115

PubMed Identifier: 35507017

Publication URI: http://europepmc.org/abstract/MED/35507017

Type: Journal Article/Review

Parent Publication: Clinical Cancer Research

Issue: 14

ISSN: 1078-0432